Cargando…
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
There is a controversy about the performance of blood tests for the diagnostic of metabolic liver disease in patients with type-2-diabetes in comparison with patients without type-2-diabetes. These indirect comparisons assumed that the gold-standard is binary, whereas fibrosis stages, steatosis and...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337110/ https://www.ncbi.nlm.nih.gov/pubmed/31789950 http://dx.doi.org/10.1097/MEG.0000000000001606 |
_version_ | 1783554448418668544 |
---|---|
author | Poynard, Thierry Peta, Valentina Deckmyn, Olivier Pais, Raluca Ngo, Yen Charlotte, Frederic Ngo, An Munteanu, Mona Imbert-Bismut, Françoise Monneret, Denis Housset, Chantal Thabut, Dominique Valla, Dominique Boitard, Christian Castera, Laurent Ratziu, Vlad |
author_facet | Poynard, Thierry Peta, Valentina Deckmyn, Olivier Pais, Raluca Ngo, Yen Charlotte, Frederic Ngo, An Munteanu, Mona Imbert-Bismut, Françoise Monneret, Denis Housset, Chantal Thabut, Dominique Valla, Dominique Boitard, Christian Castera, Laurent Ratziu, Vlad |
author_sort | Poynard, Thierry |
collection | PubMed |
description | There is a controversy about the performance of blood tests for the diagnostic of metabolic liver disease in patients with type-2-diabetes in comparison with patients without type-2-diabetes. These indirect comparisons assumed that the gold-standard is binary, whereas fibrosis stages, steatosis and nonalcoholic-steato-hepatitis (NASH) grades use an ordinal scale. The primary aim was to compare the diagnostic performances of FibroTest in type-2-diabetes vs. controls matched on gender, age, fibrosis stages and obesity, and taking into account the spectrum effect by Obuchowski measure. METHODS: Data were retrospectively compared among patients prospectively included, with simultaneous biopsy and blindly assessed FibroTest, SteatoTest-2 and NashTest-2. The secondary aim was to construct an index (SpectrumF3F4-Index) to predict an adjusted-area under the receiver operating curve (AUROC) for F3F4 diagnosis from the prevalences of fibrosis stages, permitting to reduce the spectrum effect when performances of FibroTest, transient elastography and magnetic resonance elastography are indirectly compared. RESULTS: In 505 patients at risk of NASH, the Obuchowski measures [95% confidence interval (CI)] of FibroTest, SteatoTest-2 and NashTest-2 were all equivalent in 136 type-2-diabetes cases vs. 369 matched controls: 0.871 (0.837–0.905), vs. 0.880 (0.879–0.881), 0.835 (0.797–0.873) vs. 0.806 (0.780–0.832) and 0.829 (0.793–0.865) vs. 0.855 (0.829–0.869), respectively. Standard-AUROCs (95% CI) were 0.932 (0.898–0.965), 0.872 (0.837–0.907) and 0.834 (0.699–0.969) and reduced after adjustment by SpectrumF3F4-Index to 0.794 (0.749–0.838), 0.767 (0.750–0.783) and 0.773 (0.725–0.822) for transient, magnetic resonance elastography and FibroTest, respectively. CONCLUSIONS: When compared by Obuchowski measures, the performances of tests were not different in patients with T2-diabetes vs. patients without T2-diabetes. When individual data are not available, adjusted-AUROCs reduced the spectrum effect. |
format | Online Article Text |
id | pubmed-7337110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams And Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73371102020-07-13 Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes Poynard, Thierry Peta, Valentina Deckmyn, Olivier Pais, Raluca Ngo, Yen Charlotte, Frederic Ngo, An Munteanu, Mona Imbert-Bismut, Françoise Monneret, Denis Housset, Chantal Thabut, Dominique Valla, Dominique Boitard, Christian Castera, Laurent Ratziu, Vlad Eur J Gastroenterol Hepatol Original Articles: Hepatology There is a controversy about the performance of blood tests for the diagnostic of metabolic liver disease in patients with type-2-diabetes in comparison with patients without type-2-diabetes. These indirect comparisons assumed that the gold-standard is binary, whereas fibrosis stages, steatosis and nonalcoholic-steato-hepatitis (NASH) grades use an ordinal scale. The primary aim was to compare the diagnostic performances of FibroTest in type-2-diabetes vs. controls matched on gender, age, fibrosis stages and obesity, and taking into account the spectrum effect by Obuchowski measure. METHODS: Data were retrospectively compared among patients prospectively included, with simultaneous biopsy and blindly assessed FibroTest, SteatoTest-2 and NashTest-2. The secondary aim was to construct an index (SpectrumF3F4-Index) to predict an adjusted-area under the receiver operating curve (AUROC) for F3F4 diagnosis from the prevalences of fibrosis stages, permitting to reduce the spectrum effect when performances of FibroTest, transient elastography and magnetic resonance elastography are indirectly compared. RESULTS: In 505 patients at risk of NASH, the Obuchowski measures [95% confidence interval (CI)] of FibroTest, SteatoTest-2 and NashTest-2 were all equivalent in 136 type-2-diabetes cases vs. 369 matched controls: 0.871 (0.837–0.905), vs. 0.880 (0.879–0.881), 0.835 (0.797–0.873) vs. 0.806 (0.780–0.832) and 0.829 (0.793–0.865) vs. 0.855 (0.829–0.869), respectively. Standard-AUROCs (95% CI) were 0.932 (0.898–0.965), 0.872 (0.837–0.907) and 0.834 (0.699–0.969) and reduced after adjustment by SpectrumF3F4-Index to 0.794 (0.749–0.838), 0.767 (0.750–0.783) and 0.773 (0.725–0.822) for transient, magnetic resonance elastography and FibroTest, respectively. CONCLUSIONS: When compared by Obuchowski measures, the performances of tests were not different in patients with T2-diabetes vs. patients without T2-diabetes. When individual data are not available, adjusted-AUROCs reduced the spectrum effect. Lippincott Williams And Wilkins 2019-11-25 2020-08 /pmc/articles/PMC7337110/ /pubmed/31789950 http://dx.doi.org/10.1097/MEG.0000000000001606 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles: Hepatology Poynard, Thierry Peta, Valentina Deckmyn, Olivier Pais, Raluca Ngo, Yen Charlotte, Frederic Ngo, An Munteanu, Mona Imbert-Bismut, Françoise Monneret, Denis Housset, Chantal Thabut, Dominique Valla, Dominique Boitard, Christian Castera, Laurent Ratziu, Vlad Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title_full | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title_fullStr | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title_full_unstemmed | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title_short | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
title_sort | performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
topic | Original Articles: Hepatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337110/ https://www.ncbi.nlm.nih.gov/pubmed/31789950 http://dx.doi.org/10.1097/MEG.0000000000001606 |
work_keys_str_mv | AT poynardthierry performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT petavalentina performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT deckmynolivier performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT paisraluca performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT ngoyen performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT charlottefrederic performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT ngoan performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT munteanumona performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT imbertbismutfrancoise performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT monneretdenis performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT houssetchantal performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT thabutdominique performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT valladominique performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT boitardchristian performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT casteralaurent performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes AT ratziuvlad performanceofliverbiomarkersinpatientsatriskofnonalcoholicsteatohepatitisaccordingtopresenceoftype2diabetes |